Sodium phenylbutyrate - GMP-Orphan

Drug Profile

Sodium phenylbutyrate - GMP-Orphan

Alternative Names: Satisma

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GMP-Orphan SAS
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Spinal muscular atrophy

Most Recent Events

  • 07 Nov 2016 Chemical structure information added
  • 03 Jul 2014 GMP-Orphan has published patent for phenyl butyrate for a motor neuron disease or a metabolic disease in USA
  • 22 Jun 2012 Preclinical trials in Spinal muscular atrophy (In adolescents, In children, In infants) in France (unspecified route) after June 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top